Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Radiation Oncology | 61 | 2024 | 563 | 13.150 |
Why?
|
Prostatic Neoplasms | 178 | 2024 | 11107 | 6.580 |
Why?
|
Periodicals as Topic | 22 | 2021 | 1463 | 5.120 |
Why?
|
Urinary Bladder Neoplasms | 59 | 2024 | 2223 | 4.150 |
Why?
|
Prostate-Specific Antigen | 73 | 2024 | 2465 | 3.830 |
Why?
|
Bibliometrics | 11 | 2021 | 352 | 2.860 |
Why?
|
Cystectomy | 37 | 2023 | 634 | 2.390 |
Why?
|
Brachytherapy | 26 | 2022 | 1223 | 2.120 |
Why?
|
Radiotherapy Dosage | 52 | 2016 | 2897 | 2.050 |
Why?
|
Editorial Policies | 9 | 2021 | 458 | 1.910 |
Why?
|
Carcinoma, Transitional Cell | 20 | 2023 | 782 | 1.880 |
Why?
|
Radiotherapy, Conformal | 19 | 2015 | 548 | 1.840 |
Why?
|
Information Storage and Retrieval | 6 | 2019 | 819 | 1.800 |
Why?
|
Prostatectomy | 40 | 2023 | 1825 | 1.600 |
Why?
|
Authorship | 7 | 2021 | 284 | 1.560 |
Why?
|
Radiotherapy | 21 | 2020 | 1497 | 1.520 |
Why?
|
Peer Review, Research | 6 | 2021 | 339 | 1.500 |
Why?
|
Urinary Bladder | 22 | 2023 | 1151 | 1.500 |
Why?
|
Adenocarcinoma | 34 | 2015 | 6345 | 1.500 |
Why?
|
Androgen Antagonists | 25 | 2022 | 1409 | 1.460 |
Why?
|
Publishing | 7 | 2021 | 832 | 1.390 |
Why?
|
Radiotherapy, Intensity-Modulated | 16 | 2017 | 801 | 1.340 |
Why?
|
Journal Impact Factor | 5 | 2018 | 153 | 1.320 |
Why?
|
Salvage Therapy | 23 | 2020 | 1263 | 1.150 |
Why?
|
Watchful Waiting | 10 | 2023 | 491 | 1.090 |
Why?
|
Neoplasm Invasiveness | 41 | 2024 | 3593 | 1.070 |
Why?
|
Radiobiology | 3 | 2015 | 90 | 1.030 |
Why?
|
Combined Modality Therapy | 54 | 2020 | 8516 | 0.970 |
Why?
|
Scientific Misconduct | 2 | 2017 | 74 | 0.970 |
Why?
|
Publications | 2 | 2019 | 194 | 0.930 |
Why?
|
Neoplasm Staging | 62 | 2020 | 11118 | 0.890 |
Why?
|
Antineoplastic Agents, Hormonal | 14 | 2015 | 1520 | 0.870 |
Why?
|
Muscle Neoplasms | 3 | 2013 | 130 | 0.840 |
Why?
|
Neoplasms | 22 | 2023 | 22131 | 0.810 |
Why?
|
Medically Underserved Area | 2 | 2014 | 254 | 0.800 |
Why?
|
Dose-Response Relationship, Radiation | 15 | 2016 | 880 | 0.780 |
Why?
|
Prostate | 21 | 2023 | 1773 | 0.770 |
Why?
|
Guidelines as Topic | 3 | 2020 | 1386 | 0.770 |
Why?
|
Chemotherapy, Adjuvant | 22 | 2020 | 3514 | 0.730 |
Why?
|
Male | 234 | 2024 | 360402 | 0.720 |
Why?
|
Humans | 304 | 2024 | 760740 | 0.710 |
Why?
|
Radiosurgery | 6 | 2024 | 1339 | 0.710 |
Why?
|
Protons | 8 | 2014 | 1112 | 0.700 |
Why?
|
Forecasting | 7 | 2020 | 2924 | 0.690 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 23 | 2023 | 11735 | 0.680 |
Why?
|
Disease-Free Survival | 36 | 2024 | 6807 | 0.650 |
Why?
|
Ablation Techniques | 3 | 2020 | 246 | 0.640 |
Why?
|
Radiotherapy, Adjuvant | 20 | 2020 | 1784 | 0.640 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 11 | 2023 | 1655 | 0.640 |
Why?
|
Evidence-Based Medicine | 11 | 2020 | 3680 | 0.640 |
Why?
|
Treatment Failure | 21 | 2016 | 2635 | 0.630 |
Why?
|
Kaplan-Meier Estimate | 10 | 2017 | 6473 | 0.630 |
Why?
|
Neoplasm Recurrence, Local | 35 | 2022 | 9277 | 0.630 |
Why?
|
Employment | 3 | 2016 | 1113 | 0.630 |
Why?
|
Organs at Risk | 7 | 2017 | 359 | 0.590 |
Why?
|
Physiological Phenomena | 1 | 2017 | 18 | 0.580 |
Why?
|
Publication Bias | 2 | 2015 | 160 | 0.560 |
Why?
|
Neoadjuvant Therapy | 11 | 2018 | 2827 | 0.560 |
Why?
|
Neoplasm Metastasis | 13 | 2021 | 4910 | 0.550 |
Why?
|
Specialty Boards | 2 | 2016 | 235 | 0.550 |
Why?
|
Randomized Controlled Trials as Topic | 19 | 2019 | 10203 | 0.540 |
Why?
|
Technology, Radiologic | 3 | 2016 | 160 | 0.530 |
Why?
|
Developing Countries | 6 | 2018 | 2868 | 0.530 |
Why?
|
Internship and Residency | 4 | 2020 | 5878 | 0.530 |
Why?
|
Rectum | 12 | 2017 | 891 | 0.520 |
Why?
|
Peer Review | 2 | 2018 | 217 | 0.520 |
Why?
|
Foreign Medical Graduates | 1 | 2016 | 77 | 0.500 |
Why?
|
Treatment Outcome | 66 | 2023 | 64572 | 0.500 |
Why?
|
Urination Disorders | 4 | 2016 | 238 | 0.480 |
Why?
|
Muscle, Smooth | 7 | 2014 | 927 | 0.470 |
Why?
|
Immunity | 1 | 2020 | 994 | 0.470 |
Why?
|
Internationality | 1 | 2020 | 1000 | 0.460 |
Why?
|
Conflict of Interest | 1 | 2019 | 554 | 0.460 |
Why?
|
Paclitaxel | 6 | 2023 | 1730 | 0.460 |
Why?
|
Physics | 1 | 2014 | 91 | 0.450 |
Why?
|
Aged | 113 | 2024 | 169092 | 0.450 |
Why?
|
Health Care Costs | 4 | 2015 | 3238 | 0.450 |
Why?
|
Carcinoma, Ductal | 2 | 2013 | 97 | 0.440 |
Why?
|
Seminoma | 4 | 2019 | 134 | 0.440 |
Why?
|
Disclosure | 1 | 2019 | 747 | 0.430 |
Why?
|
Quality of Life | 18 | 2017 | 13359 | 0.430 |
Why?
|
Ethics, Professional | 1 | 2013 | 100 | 0.430 |
Why?
|
Societies, Medical | 9 | 2024 | 3901 | 0.430 |
Why?
|
Double-Blind Method | 4 | 2020 | 12333 | 0.420 |
Why?
|
Urologic Surgical Procedures | 5 | 2018 | 296 | 0.420 |
Why?
|
Consensus | 7 | 2020 | 3117 | 0.410 |
Why?
|
Cancer Care Facilities | 5 | 2016 | 422 | 0.410 |
Why?
|
Certification | 1 | 2016 | 418 | 0.410 |
Why?
|
Radiation Injuries | 8 | 2017 | 1189 | 0.410 |
Why?
|
Testicular Neoplasms | 6 | 2019 | 800 | 0.410 |
Why?
|
Orchiectomy | 8 | 2019 | 463 | 0.410 |
Why?
|
Postoperative Care | 5 | 2018 | 1467 | 0.410 |
Why?
|
Ethics, Research | 1 | 2013 | 176 | 0.400 |
Why?
|
Models, Economic | 1 | 2016 | 714 | 0.390 |
Why?
|
Disaster Planning | 1 | 2018 | 557 | 0.390 |
Why?
|
Disasters | 1 | 2018 | 520 | 0.390 |
Why?
|
Terminology as Topic | 2 | 2016 | 1528 | 0.390 |
Why?
|
Diffusion of Innovation | 4 | 2019 | 729 | 0.370 |
Why?
|
Carcinoma | 5 | 2017 | 2328 | 0.360 |
Why?
|
Awards and Prizes | 1 | 2015 | 360 | 0.360 |
Why?
|
Technology Transfer | 1 | 2010 | 42 | 0.360 |
Why?
|
Middle Aged | 103 | 2024 | 220603 | 0.350 |
Why?
|
Neoplasms, Hormone-Dependent | 3 | 2010 | 410 | 0.350 |
Why?
|
Neoplasms, Experimental | 7 | 1997 | 1226 | 0.350 |
Why?
|
Urology | 6 | 2020 | 400 | 0.340 |
Why?
|
Leuprolide | 6 | 2011 | 312 | 0.340 |
Why?
|
Medicine | 2 | 2016 | 942 | 0.330 |
Why?
|
Aged, 80 and over | 44 | 2020 | 58919 | 0.330 |
Why?
|
Program Development | 1 | 2015 | 1293 | 0.330 |
Why?
|
Attitude | 1 | 2014 | 772 | 0.330 |
Why?
|
Quality Improvement | 3 | 2021 | 3801 | 0.330 |
Why?
|
Technology Assessment, Biomedical | 1 | 2012 | 306 | 0.320 |
Why?
|
Early Detection of Cancer | 5 | 2024 | 3196 | 0.320 |
Why?
|
Follow-Up Studies | 44 | 2024 | 39062 | 0.320 |
Why?
|
Biomedical Research | 5 | 2018 | 3426 | 0.320 |
Why?
|
Hospitals, General | 2 | 2017 | 798 | 0.310 |
Why?
|
Cisplatin | 11 | 2023 | 1650 | 0.300 |
Why?
|
Cystoscopy | 5 | 2006 | 130 | 0.300 |
Why?
|
Neoplasms, Second Primary | 1 | 2016 | 1051 | 0.300 |
Why?
|
Relative Biological Effectiveness | 4 | 2017 | 311 | 0.290 |
Why?
|
Internet | 1 | 2019 | 3094 | 0.280 |
Why?
|
Lymphoma | 3 | 2015 | 1899 | 0.280 |
Why?
|
Pelvis | 9 | 2017 | 732 | 0.280 |
Why?
|
Survival Rate | 24 | 2017 | 12719 | 0.280 |
Why?
|
Time Factors | 28 | 2017 | 39908 | 0.270 |
Why?
|
History, 20th Century | 4 | 2019 | 2764 | 0.270 |
Why?
|
Biopsy | 18 | 2023 | 6763 | 0.270 |
Why?
|
Multivariate Analysis | 20 | 2017 | 12043 | 0.270 |
Why?
|
Neoplasm Transplantation | 13 | 1997 | 2010 | 0.260 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2020 | 4010 | 0.260 |
Why?
|
Plagiarism | 2 | 2017 | 22 | 0.260 |
Why?
|
Clinical Trials as Topic | 7 | 2018 | 7995 | 0.260 |
Why?
|
BCG Vaccine | 1 | 2008 | 369 | 0.260 |
Why?
|
Actuarial Analysis | 8 | 2004 | 372 | 0.250 |
Why?
|
Congresses as Topic | 2 | 2024 | 802 | 0.250 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2010 | 709 | 0.240 |
Why?
|
Urodynamics | 2 | 2003 | 344 | 0.240 |
Why?
|
Physicians | 1 | 2023 | 4583 | 0.240 |
Why?
|
Patient Selection | 12 | 2017 | 4237 | 0.230 |
Why?
|
Medical Oncology | 4 | 2020 | 2317 | 0.220 |
Why?
|
Self Report | 2 | 2015 | 3727 | 0.220 |
Why?
|
Urinary Bladder Diseases | 2 | 2003 | 167 | 0.220 |
Why?
|
United States | 29 | 2024 | 72292 | 0.220 |
Why?
|
Disease Progression | 9 | 2023 | 13495 | 0.210 |
Why?
|
History, 21st Century | 2 | 2019 | 1566 | 0.210 |
Why?
|
Radiometry | 5 | 2017 | 812 | 0.210 |
Why?
|
Mice, Nude | 13 | 2005 | 3606 | 0.200 |
Why?
|
Urinary Retention | 1 | 2003 | 106 | 0.200 |
Why?
|
Medical Illustration | 2 | 2013 | 135 | 0.190 |
Why?
|
Transurethral Resection of Prostate | 1 | 2022 | 79 | 0.190 |
Why?
|
Androgens | 3 | 2021 | 1285 | 0.190 |
Why?
|
Radiotherapy, High-Energy | 5 | 2007 | 228 | 0.190 |
Why?
|
Proportional Hazards Models | 11 | 2017 | 12448 | 0.190 |
Why?
|
Mass Screening | 3 | 2024 | 5425 | 0.190 |
Why?
|
Radiation-Sensitizing Agents | 5 | 2013 | 349 | 0.190 |
Why?
|
Practice Guidelines as Topic | 8 | 2020 | 7390 | 0.190 |
Why?
|
Survivors | 3 | 2017 | 2373 | 0.190 |
Why?
|
Urethra | 7 | 2022 | 403 | 0.180 |
Why?
|
Pathology, Clinical | 2 | 2014 | 376 | 0.180 |
Why?
|
Clinical Competence | 1 | 2016 | 4790 | 0.180 |
Why?
|
Prognosis | 22 | 2024 | 29601 | 0.170 |
Why?
|
Pandemics | 1 | 2020 | 8652 | 0.170 |
Why?
|
Data Interpretation, Statistical | 5 | 2015 | 2689 | 0.170 |
Why?
|
Survival Analysis | 12 | 2017 | 10072 | 0.170 |
Why?
|
Sex Reassignment Surgery | 1 | 2023 | 164 | 0.170 |
Why?
|
Decision Support Techniques | 1 | 2010 | 1999 | 0.170 |
Why?
|
Lymph Nodes | 7 | 2017 | 3461 | 0.170 |
Why?
|
Nomograms | 2 | 2013 | 230 | 0.170 |
Why?
|
Muscles | 5 | 2023 | 1573 | 0.160 |
Why?
|
Clinical Trials, Phase III as Topic | 2 | 2014 | 857 | 0.160 |
Why?
|
Anilides | 2 | 2017 | 411 | 0.160 |
Why?
|
Antineoplastic Agents | 11 | 2019 | 13635 | 0.160 |
Why?
|
Movement | 3 | 2016 | 1476 | 0.150 |
Why?
|
Tumor Burden | 5 | 2014 | 1892 | 0.150 |
Why?
|
Fluorouracil | 4 | 2018 | 1642 | 0.150 |
Why?
|
Risk Factors | 21 | 2023 | 74128 | 0.150 |
Why?
|
Adenocarcinoma, Mucinous | 1 | 2022 | 517 | 0.150 |
Why?
|
Quarantine | 1 | 2020 | 182 | 0.150 |
Why?
|
Tosyl Compounds | 2 | 2017 | 115 | 0.150 |
Why?
|
Career Choice | 2 | 2016 | 757 | 0.150 |
Why?
|
Radiography | 5 | 2018 | 6961 | 0.150 |
Why?
|
Postoperative Complications | 3 | 2014 | 15609 | 0.150 |
Why?
|
Female | 51 | 2024 | 392203 | 0.140 |
Why?
|
Tsunamis | 1 | 2018 | 61 | 0.140 |
Why?
|
Seminal Vesicles | 6 | 2016 | 103 | 0.140 |
Why?
|
Lymphatic Metastasis | 8 | 2017 | 2913 | 0.140 |
Why?
|
Risk | 6 | 2020 | 9603 | 0.140 |
Why?
|
Fraud | 1 | 2017 | 66 | 0.140 |
Why?
|
Lymphatic Irradiation | 2 | 2008 | 115 | 0.140 |
Why?
|
X-Ray Therapy | 1 | 2016 | 8 | 0.140 |
Why?
|
Texas | 1 | 2018 | 403 | 0.140 |
Why?
|
Career Mobility | 1 | 2019 | 259 | 0.140 |
Why?
|
Puerto Rico | 1 | 2018 | 378 | 0.140 |
Why?
|
Deoxycytidine | 2 | 2018 | 878 | 0.140 |
Why?
|
Relief Work | 1 | 2018 | 130 | 0.140 |
Why?
|
Abortion, Induced | 1 | 2022 | 461 | 0.140 |
Why?
|
Retrospective Studies | 30 | 2023 | 80583 | 0.140 |
Why?
|
Clinical Trials, Phase IV as Topic | 1 | 2016 | 29 | 0.130 |
Why?
|
Cyclonic Storms | 1 | 2018 | 116 | 0.130 |
Why?
|
Hematuria | 3 | 2013 | 232 | 0.130 |
Why?
|
Adult | 35 | 2022 | 220995 | 0.130 |
Why?
|
Colorectal Neoplasms | 1 | 2016 | 6927 | 0.130 |
Why?
|
Risk Assessment | 7 | 2021 | 23974 | 0.130 |
Why?
|
Hodgkin Disease | 2 | 2015 | 1378 | 0.130 |
Why?
|
Predictive Value of Tests | 8 | 2016 | 15250 | 0.130 |
Why?
|
Osteoporosis | 3 | 2020 | 1604 | 0.130 |
Why?
|
Osteoporotic Fractures | 1 | 2020 | 410 | 0.130 |
Why?
|
Rectal Neoplasms | 2 | 2008 | 1156 | 0.130 |
Why?
|
Paris | 1 | 2015 | 41 | 0.130 |
Why?
|
Procarbazine | 1 | 2015 | 172 | 0.130 |
Why?
|
Mechlorethamine | 1 | 2015 | 129 | 0.130 |
Why?
|
Dexamethasone | 1 | 2003 | 1946 | 0.120 |
Why?
|
Correspondence as Topic | 1 | 2015 | 34 | 0.120 |
Why?
|
Information Management | 1 | 2015 | 100 | 0.120 |
Why?
|
Earthquakes | 1 | 2018 | 191 | 0.120 |
Why?
|
Competitive Behavior | 1 | 2015 | 78 | 0.120 |
Why?
|
Paintings | 1 | 2016 | 103 | 0.120 |
Why?
|
Multicenter Studies as Topic | 3 | 2014 | 1700 | 0.120 |
Why?
|
Research | 3 | 2013 | 1977 | 0.120 |
Why?
|
Reimbursement Mechanisms | 2 | 2012 | 667 | 0.120 |
Why?
|
Deception | 1 | 2015 | 99 | 0.120 |
Why?
|
Cohort Studies | 13 | 2023 | 41464 | 0.120 |
Why?
|
Urothelium | 1 | 2016 | 269 | 0.120 |
Why?
|
School Admission Criteria | 1 | 2015 | 107 | 0.120 |
Why?
|
Body Mass Index | 3 | 2010 | 12942 | 0.120 |
Why?
|
PubMed | 1 | 2015 | 129 | 0.120 |
Why?
|
Community Health Centers | 1 | 2017 | 460 | 0.110 |
Why?
|
Retraction of Publication as Topic | 1 | 2013 | 10 | 0.110 |
Why?
|
Sensitivity and Specificity | 10 | 2016 | 14649 | 0.110 |
Why?
|
Urinary Incontinence | 4 | 2015 | 489 | 0.110 |
Why?
|
Photons | 3 | 2012 | 589 | 0.110 |
Why?
|
Advisory Committees | 2 | 2015 | 787 | 0.110 |
Why?
|
Japan | 1 | 2018 | 1372 | 0.110 |
Why?
|
Health Services Needs and Demand | 2 | 2014 | 1400 | 0.110 |
Why?
|
Gastrointestinal Hemorrhage | 3 | 2016 | 1116 | 0.110 |
Why?
|
Glucocorticoids | 1 | 2003 | 2160 | 0.110 |
Why?
|
Urinary Catheterization | 1 | 2014 | 193 | 0.110 |
Why?
|
Biological Science Disciplines | 1 | 2013 | 57 | 0.110 |
Why?
|
Testosterone | 2 | 2002 | 2472 | 0.110 |
Why?
|
Nitriles | 2 | 2017 | 971 | 0.110 |
Why?
|
Nasopharyngeal Neoplasms | 1 | 2015 | 290 | 0.110 |
Why?
|
Neoplasms, Radiation-Induced | 3 | 2012 | 549 | 0.100 |
Why?
|
Selection Bias | 1 | 2014 | 359 | 0.100 |
Why?
|
Intestinal Diseases | 4 | 2016 | 503 | 0.100 |
Why?
|
Age Factors | 12 | 2019 | 18381 | 0.100 |
Why?
|
New York City | 1 | 2015 | 731 | 0.100 |
Why?
|
Vincristine | 1 | 2015 | 1036 | 0.100 |
Why?
|
History, 19th Century | 1 | 2015 | 718 | 0.100 |
Why?
|
Program Evaluation | 3 | 2016 | 2486 | 0.100 |
Why?
|
Microtubule-Associated Proteins | 2 | 2010 | 1074 | 0.100 |
Why?
|
Antineoplastic Agents, Phytogenic | 2 | 2007 | 620 | 0.100 |
Why?
|
Radiation Dosage | 3 | 2017 | 1956 | 0.100 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2014 | 629 | 0.100 |
Why?
|
Public Policy | 1 | 2016 | 557 | 0.100 |
Why?
|
Developed Countries | 3 | 2022 | 450 | 0.100 |
Why?
|
Prospective Studies | 12 | 2022 | 54364 | 0.100 |
Why?
|
Catheters, Indwelling | 1 | 2014 | 426 | 0.100 |
Why?
|
Pathology | 1 | 2015 | 269 | 0.100 |
Why?
|
Writing | 1 | 2013 | 199 | 0.100 |
Why?
|
Professional Role | 1 | 2014 | 313 | 0.090 |
Why?
|
Reproducibility of Results | 6 | 2017 | 20077 | 0.090 |
Why?
|
Reference Standards | 2 | 2005 | 1003 | 0.090 |
Why?
|
Urinary Diversion | 2 | 2017 | 134 | 0.090 |
Why?
|
Urethral Neoplasms | 1 | 2011 | 37 | 0.090 |
Why?
|
Mice, Inbred C3H | 6 | 1994 | 913 | 0.090 |
Why?
|
Analysis of Variance | 6 | 2013 | 6223 | 0.090 |
Why?
|
Review Literature as Topic | 1 | 2013 | 347 | 0.090 |
Why?
|
Breast Neoplasms | 4 | 2015 | 20988 | 0.090 |
Why?
|
Gonadotropin-Releasing Hormone | 3 | 2008 | 1148 | 0.090 |
Why?
|
Digital Rectal Examination | 1 | 2010 | 41 | 0.090 |
Why?
|
Urogenital System | 1 | 2010 | 88 | 0.090 |
Why?
|
Efficiency, Organizational | 1 | 2015 | 695 | 0.090 |
Why?
|
Health Care Surveys | 2 | 2012 | 2422 | 0.090 |
Why?
|
Radiology | 2 | 2016 | 2113 | 0.090 |
Why?
|
Prednisone | 1 | 2015 | 1562 | 0.090 |
Why?
|
Pelvic Bones | 2 | 2010 | 270 | 0.090 |
Why?
|
Organ Size | 2 | 2015 | 2252 | 0.080 |
Why?
|
Ultrasonography, Interventional | 2 | 2012 | 1496 | 0.080 |
Why?
|
Immobilization | 1 | 2010 | 229 | 0.080 |
Why?
|
Sexual Dysfunction, Physiological | 4 | 2016 | 361 | 0.080 |
Why?
|
Delivery of Health Care | 2 | 2020 | 5334 | 0.080 |
Why?
|
Postoperative Period | 2 | 2011 | 1812 | 0.080 |
Why?
|
Transplantation, Heterologous | 7 | 1993 | 2382 | 0.080 |
Why?
|
Femur | 3 | 2012 | 1307 | 0.080 |
Why?
|
Ethics, Clinical | 1 | 2009 | 101 | 0.080 |
Why?
|
Rotation | 1 | 2010 | 517 | 0.080 |
Why?
|
Evidence-Based Practice | 1 | 2013 | 494 | 0.080 |
Why?
|
Information Dissemination | 2 | 2015 | 1126 | 0.080 |
Why?
|
Palladium | 3 | 2011 | 67 | 0.080 |
Why?
|
Boston | 4 | 2017 | 9313 | 0.080 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 1996 | 1372 | 0.080 |
Why?
|
SEER Program | 4 | 2019 | 1450 | 0.080 |
Why?
|
Necrosis | 1 | 2012 | 1610 | 0.080 |
Why?
|
Comparative Effectiveness Research | 1 | 2013 | 708 | 0.080 |
Why?
|
Remission Induction | 6 | 2015 | 2391 | 0.080 |
Why?
|
Iodine Radioisotopes | 4 | 2011 | 1031 | 0.070 |
Why?
|
Cost Control | 1 | 2010 | 627 | 0.070 |
Why?
|
Propensity Score | 3 | 2023 | 1912 | 0.070 |
Why?
|
Oxides | 1 | 2009 | 401 | 0.070 |
Why?
|
Odds Ratio | 3 | 2014 | 9644 | 0.070 |
Why?
|
Precancerous Conditions | 1 | 2014 | 982 | 0.070 |
Why?
|
Radioisotopes | 3 | 2011 | 499 | 0.070 |
Why?
|
Fibrosarcoma | 4 | 1993 | 308 | 0.070 |
Why?
|
Subcutaneous Fat | 1 | 2010 | 393 | 0.070 |
Why?
|
Carcinoma, Squamous Cell | 5 | 2012 | 4021 | 0.070 |
Why?
|
Health Services Accessibility | 2 | 2015 | 5430 | 0.070 |
Why?
|
Interdisciplinary Communication | 1 | 2012 | 928 | 0.070 |
Why?
|
Guideline Adherence | 2 | 2013 | 2218 | 0.070 |
Why?
|
Pregnancy | 2 | 2022 | 29869 | 0.070 |
Why?
|
Radionuclide Imaging | 4 | 2012 | 1972 | 0.070 |
Why?
|
Body Composition | 3 | 2008 | 2426 | 0.070 |
Why?
|
Biomedical Technology | 1 | 2008 | 210 | 0.060 |
Why?
|
Epidemiologic Methods | 1 | 2010 | 1335 | 0.060 |
Why?
|
Molecular Targeted Therapy | 2 | 2018 | 2812 | 0.060 |
Why?
|
Incidence | 6 | 2017 | 21339 | 0.060 |
Why?
|
Spermatic Cord | 2 | 1996 | 23 | 0.060 |
Why?
|
Quality Assurance, Health Care | 2 | 2013 | 2164 | 0.060 |
Why?
|
Mice | 20 | 2010 | 81368 | 0.060 |
Why?
|
Regression Analysis | 4 | 2008 | 6339 | 0.060 |
Why?
|
Bone Neoplasms | 3 | 2011 | 2527 | 0.060 |
Why?
|
Particle Size | 1 | 2009 | 1648 | 0.060 |
Why?
|
Genital Neoplasms, Male | 2 | 1996 | 68 | 0.060 |
Why?
|
Statistics, Nonparametric | 3 | 2016 | 2851 | 0.060 |
Why?
|
Lymph Node Excision | 4 | 2017 | 1269 | 0.060 |
Why?
|
Sperm Count | 1 | 2005 | 229 | 0.060 |
Why?
|
Neovascularization, Physiologic | 1 | 2012 | 1349 | 0.060 |
Why?
|
Wales | 1 | 2024 | 87 | 0.060 |
Why?
|
International Agencies | 2 | 2015 | 242 | 0.060 |
Why?
|
Gastrointestinal Tract | 1 | 2010 | 834 | 0.060 |
Why?
|
Diagnostic Imaging | 1 | 2018 | 3527 | 0.060 |
Why?
|
Education, Medical | 1 | 2016 | 1725 | 0.060 |
Why?
|
Doxorubicin | 1 | 1991 | 2224 | 0.060 |
Why?
|
Income | 1 | 2012 | 1870 | 0.060 |
Why?
|
Algorithms | 5 | 2018 | 14024 | 0.060 |
Why?
|
Kidney Pelvis | 1 | 2004 | 186 | 0.050 |
Why?
|
Ureteral Neoplasms | 1 | 2004 | 107 | 0.050 |
Why?
|
Specialization | 1 | 2008 | 778 | 0.050 |
Why?
|
United States Food and Drug Administration | 1 | 2012 | 1661 | 0.050 |
Why?
|
Decision Making | 2 | 2016 | 3919 | 0.050 |
Why?
|
Kidney Neoplasms | 2 | 2014 | 4252 | 0.050 |
Why?
|
Neoplasm, Residual | 3 | 2004 | 1008 | 0.050 |
Why?
|
Longevity | 1 | 1991 | 1064 | 0.050 |
Why?
|
Penis | 2 | 2016 | 210 | 0.050 |
Why?
|
Head and Neck Neoplasms | 2 | 2012 | 2894 | 0.050 |
Why?
|
England | 1 | 2024 | 526 | 0.050 |
Why?
|
Tumor Cells, Cultured | 5 | 1997 | 6126 | 0.050 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2012 | 1187 | 0.050 |
Why?
|
Patient Participation | 1 | 2012 | 1443 | 0.050 |
Why?
|
Germinoma | 1 | 2003 | 132 | 0.050 |
Why?
|
Erectile Dysfunction | 3 | 2007 | 444 | 0.050 |
Why?
|
Equipment Design | 1 | 2010 | 3501 | 0.050 |
Why?
|
Mediastinum | 1 | 2003 | 266 | 0.050 |
Why?
|
Life Tables | 1 | 2002 | 364 | 0.050 |
Why?
|
Antineoplastic Protocols | 1 | 2001 | 48 | 0.050 |
Why?
|
Patient Compliance | 1 | 2012 | 2688 | 0.050 |
Why?
|
Diagnosis, Differential | 5 | 2022 | 12966 | 0.050 |
Why?
|
Tomography, X-Ray Computed | 8 | 2017 | 20556 | 0.050 |
Why?
|
Neoplasm Proteins | 3 | 2010 | 3607 | 0.050 |
Why?
|
Clinical Protocols | 3 | 1998 | 1436 | 0.050 |
Why?
|
Adenoviridae | 1 | 2005 | 1084 | 0.050 |
Why?
|
Patient Care Team | 1 | 2012 | 2515 | 0.050 |
Why?
|
Databases, Factual | 3 | 2019 | 7963 | 0.050 |
Why?
|
Iron | 1 | 2009 | 1790 | 0.050 |
Why?
|
Quality-Adjusted Life Years | 1 | 2007 | 1723 | 0.040 |
Why?
|
Data Collection | 1 | 2010 | 3316 | 0.040 |
Why?
|
Nanoparticles | 2 | 2009 | 1957 | 0.040 |
Why?
|
Anal Canal | 1 | 2023 | 374 | 0.040 |
Why?
|
Neoplastic Stem Cells | 2 | 2002 | 1350 | 0.040 |
Why?
|
Animals | 20 | 2010 | 168202 | 0.040 |
Why?
|
Thymosin | 1 | 2000 | 47 | 0.040 |
Why?
|
Benchmarking | 1 | 2007 | 1045 | 0.040 |
Why?
|
Mediastinal Neoplasms | 1 | 2003 | 401 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 5 | 2014 | 36401 | 0.040 |
Why?
|
Reference Values | 2 | 2005 | 4919 | 0.040 |
Why?
|
Healthcare Disparities | 1 | 2015 | 3351 | 0.040 |
Why?
|
Diphosphonates | 2 | 2002 | 635 | 0.040 |
Why?
|
Intestines | 2 | 2012 | 1909 | 0.040 |
Why?
|
Bone Density | 2 | 2004 | 3548 | 0.040 |
Why?
|
Radioactive Hazard Release | 1 | 2019 | 13 | 0.040 |
Why?
|
Chi-Square Distribution | 3 | 2016 | 3410 | 0.040 |
Why?
|
Medical Audit | 1 | 2021 | 453 | 0.040 |
Why?
|
Whole-Body Irradiation | 3 | 1990 | 432 | 0.040 |
Why?
|
State Medicine | 1 | 2021 | 216 | 0.040 |
Why?
|
Medical Informatics | 2 | 2019 | 732 | 0.040 |
Why?
|
Mucins | 1 | 2022 | 568 | 0.040 |
Why?
|
Costs and Cost Analysis | 2 | 2016 | 1663 | 0.040 |
Why?
|
Health Care Sector | 1 | 2021 | 195 | 0.040 |
Why?
|
Mammary Neoplasms, Experimental | 1 | 2002 | 506 | 0.040 |
Why?
|
Glioma | 2 | 1991 | 3452 | 0.040 |
Why?
|
Edema | 1 | 2003 | 765 | 0.040 |
Why?
|
Carcinoma, Renal Cell | 1 | 2014 | 3164 | 0.040 |
Why?
|
Image Enhancement | 1 | 2009 | 2881 | 0.040 |
Why?
|
Cell Hypoxia | 2 | 2013 | 656 | 0.040 |
Why?
|
Research Support as Topic | 2 | 2013 | 697 | 0.040 |
Why?
|
Canada | 1 | 2024 | 2120 | 0.040 |
Why?
|
Sample Size | 2 | 2016 | 838 | 0.040 |
Why?
|
Hormones | 1 | 2022 | 869 | 0.040 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2024 | 1088 | 0.040 |
Why?
|
Comorbidity | 3 | 2015 | 10507 | 0.040 |
Why?
|
Physicians, Women | 1 | 2024 | 509 | 0.040 |
Why?
|
Hydronephrosis | 2 | 2013 | 271 | 0.040 |
Why?
|
Vagina | 1 | 2023 | 841 | 0.040 |
Why?
|
Strontium Radioisotopes | 1 | 1997 | 18 | 0.040 |
Why?
|
Chromosomes, Human, Pair 11 | 1 | 1998 | 410 | 0.040 |
Why?
|
Hydrogels | 1 | 2023 | 720 | 0.040 |
Why?
|
Medical Informatics Applications | 1 | 2019 | 179 | 0.040 |
Why?
|
beta Catenin | 1 | 2022 | 1039 | 0.040 |
Why?
|
Inhibitor of Apoptosis Proteins | 2 | 2010 | 198 | 0.030 |
Why?
|
Apoptosis | 3 | 2005 | 9476 | 0.030 |
Why?
|
Posters as Topic | 1 | 2016 | 6 | 0.030 |
Why?
|
Biology | 1 | 2019 | 290 | 0.030 |
Why?
|
Folklore | 1 | 2016 | 7 | 0.030 |
Why?
|
Registries | 1 | 2013 | 8209 | 0.030 |
Why?
|
Perioperative Period | 1 | 2018 | 250 | 0.030 |
Why?
|
Urethral Stricture | 2 | 1995 | 50 | 0.030 |
Why?
|
Medicine in Literature | 1 | 2016 | 32 | 0.030 |
Why?
|
Gynecomastia | 1 | 2017 | 86 | 0.030 |
Why?
|
Loss of Heterozygosity | 1 | 1998 | 662 | 0.030 |
Why?
|
Bone Marrow Neoplasms | 1 | 1997 | 101 | 0.030 |
Why?
|
Carcinoma in Situ | 1 | 2002 | 791 | 0.030 |
Why?
|
Disease Management | 2 | 2018 | 2506 | 0.030 |
Why?
|
Radium | 1 | 2016 | 72 | 0.030 |
Why?
|
Biopsy, Needle | 2 | 2014 | 1624 | 0.030 |
Why?
|
Carboplatin | 1 | 2019 | 793 | 0.030 |
Why?
|
Death Certificates | 1 | 2016 | 167 | 0.030 |
Why?
|
Faculty, Medical | 1 | 2024 | 1204 | 0.030 |
Why?
|
Rural Health Services | 1 | 2019 | 384 | 0.030 |
Why?
|
Rectal Diseases | 2 | 2013 | 142 | 0.030 |
Why?
|
Referral and Consultation | 4 | 2013 | 3599 | 0.030 |
Why?
|
Organizations, Nonprofit | 1 | 2015 | 105 | 0.030 |
Why?
|
Cause of Death | 2 | 2016 | 3683 | 0.030 |
Why?
|
Positron-Emission Tomography | 2 | 2008 | 6483 | 0.030 |
Why?
|
Linear Energy Transfer | 1 | 2016 | 151 | 0.030 |
Why?
|
Voluntary Health Agencies | 1 | 2014 | 38 | 0.030 |
Why?
|
Fiducial Markers | 1 | 2015 | 132 | 0.030 |
Why?
|
Recurrence | 1 | 2007 | 8426 | 0.030 |
Why?
|
Vas Deferens | 2 | 2009 | 54 | 0.030 |
Why?
|
Population Surveillance | 2 | 2015 | 2597 | 0.030 |
Why?
|
New Zealand | 1 | 2014 | 358 | 0.030 |
Why?
|
Radiation-Protective Agents | 1 | 2013 | 88 | 0.030 |
Why?
|
Cross-Sectional Studies | 2 | 2016 | 26065 | 0.030 |
Why?
|
Confidence Intervals | 2 | 2013 | 2925 | 0.030 |
Why?
|
Africa | 1 | 2015 | 714 | 0.030 |
Why?
|
S Phase | 1 | 1994 | 421 | 0.030 |
Why?
|
Societies, Scientific | 1 | 2014 | 222 | 0.030 |
Why?
|
Capacity Building | 1 | 2015 | 259 | 0.030 |
Why?
|
Preoperative Care | 2 | 2009 | 2242 | 0.030 |
Why?
|
Capital Financing | 1 | 2012 | 58 | 0.030 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2005 | 5304 | 0.030 |
Why?
|
Adnexa Uteri | 1 | 2012 | 40 | 0.030 |
Why?
|
Epididymis | 1 | 1994 | 227 | 0.020 |
Why?
|
Inflammation | 1 | 2012 | 10759 | 0.020 |
Why?
|
Mice, SCID | 3 | 2010 | 2625 | 0.020 |
Why?
|
Database Management Systems | 1 | 2013 | 257 | 0.020 |
Why?
|
Research Personnel | 1 | 2016 | 588 | 0.020 |
Why?
|
Lipoproteins | 2 | 2002 | 879 | 0.020 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2006 | 3245 | 0.020 |
Why?
|
Cell Line | 5 | 1993 | 15577 | 0.020 |
Why?
|
Concanavalin A | 1 | 1991 | 190 | 0.020 |
Why?
|
Diagnosis-Related Groups | 1 | 2012 | 448 | 0.020 |
Why?
|
Decision Trees | 1 | 2013 | 504 | 0.020 |
Why?
|
Rats | 2 | 2000 | 23716 | 0.020 |
Why?
|
Marital Status | 1 | 2012 | 425 | 0.020 |
Why?
|
Ultrasonography | 1 | 2024 | 5965 | 0.020 |
Why?
|
Magnetic Resonance Spectroscopy | 3 | 2008 | 3769 | 0.020 |
Why?
|
Cell Migration Assays | 1 | 2010 | 22 | 0.020 |
Why?
|
Monte Carlo Method | 1 | 2016 | 1257 | 0.020 |
Why?
|
Ribs | 1 | 2012 | 252 | 0.020 |
Why?
|
Fecal Incontinence | 1 | 2013 | 242 | 0.020 |
Why?
|
Colic | 1 | 2010 | 44 | 0.020 |
Why?
|
Altruism | 1 | 2012 | 208 | 0.020 |
Why?
|
Hypopharyngeal Neoplasms | 1 | 1990 | 51 | 0.020 |
Why?
|
Inverted Repeat Sequences | 1 | 2010 | 60 | 0.020 |
Why?
|
Sarcoma | 3 | 1996 | 1800 | 0.020 |
Why?
|
Chemokine CXCL12 | 1 | 2012 | 454 | 0.020 |
Why?
|
Fibroblast Growth Factor 2 | 1 | 2012 | 592 | 0.020 |
Why?
|
Pubic Symphysis | 1 | 2009 | 20 | 0.020 |
Why?
|
Vinblastine | 2 | 2003 | 488 | 0.020 |
Why?
|
Length of Stay | 1 | 2003 | 6418 | 0.020 |
Why?
|
DNA, Neoplasm | 1 | 1994 | 1743 | 0.020 |
Why?
|
Skin Neoplasms | 1 | 1988 | 5811 | 0.020 |
Why?
|
Faculty | 1 | 2012 | 383 | 0.020 |
Why?
|
Prostheses and Implants | 1 | 2016 | 1269 | 0.020 |
Why?
|
Interleukin-8 | 1 | 2012 | 696 | 0.020 |
Why?
|
Area Under Curve | 1 | 2013 | 1635 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2022 | 11069 | 0.020 |
Why?
|
Defecation | 1 | 2010 | 190 | 0.020 |
Why?
|
Nephrectomy | 1 | 2014 | 937 | 0.020 |
Why?
|
Logistic Models | 2 | 2012 | 13248 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2012 | 558 | 0.020 |
Why?
|
Transplantation, Isogeneic | 1 | 1988 | 248 | 0.020 |
Why?
|
Ureter | 2 | 2004 | 368 | 0.020 |
Why?
|
Uterus | 1 | 2012 | 649 | 0.020 |
Why?
|
Lung Neoplasms | 1 | 2012 | 13383 | 0.020 |
Why?
|
Ferrosoferric Oxide | 1 | 2009 | 348 | 0.020 |
Why?
|
Maximum Tolerated Dose | 1 | 2010 | 883 | 0.020 |
Why?
|
Colitis, Ulcerative | 1 | 2000 | 1921 | 0.020 |
Why?
|
Fee-for-Service Plans | 1 | 2012 | 697 | 0.020 |
Why?
|
Hypersensitivity, Delayed | 1 | 1988 | 490 | 0.020 |
Why?
|
Ovary | 1 | 2012 | 959 | 0.020 |
Why?
|
Magnetite Nanoparticles | 1 | 2009 | 316 | 0.020 |
Why?
|
Skull | 1 | 2012 | 818 | 0.020 |
Why?
|
Dextrans | 1 | 2009 | 573 | 0.020 |
Why?
|
Brain Neoplasms | 1 | 1988 | 9026 | 0.020 |
Why?
|
Crohn Disease | 1 | 2000 | 2279 | 0.020 |
Why?
|
Medically Uninsured | 1 | 2012 | 835 | 0.020 |
Why?
|
California | 1 | 2011 | 1431 | 0.020 |
Why?
|
Severity of Illness Index | 2 | 2016 | 15829 | 0.020 |
Why?
|
Cell Survival | 1 | 1997 | 5780 | 0.020 |
Why?
|
Molecular Imaging | 1 | 2013 | 814 | 0.020 |
Why?
|
Reimbursement, Incentive | 1 | 2012 | 542 | 0.020 |
Why?
|
Health Policy | 1 | 2019 | 2682 | 0.020 |
Why?
|
Bone Marrow | 1 | 1997 | 2909 | 0.020 |
Why?
|
Organizational Objectives | 1 | 2008 | 426 | 0.020 |
Why?
|
Interleukin-1beta | 1 | 2012 | 998 | 0.020 |
Why?
|
Case-Control Studies | 2 | 2011 | 22153 | 0.020 |
Why?
|
Quality of Health Care | 1 | 2001 | 4325 | 0.020 |
Why?
|
Brain | 1 | 2012 | 27100 | 0.020 |
Why?
|
Linear Models | 1 | 2015 | 5866 | 0.020 |
Why?
|
Urologic Diseases | 1 | 2008 | 247 | 0.020 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2013 | 940 | 0.020 |
Why?
|
Neoplasms, Multiple Primary | 1 | 1989 | 592 | 0.020 |
Why?
|
Minority Groups | 1 | 2012 | 1202 | 0.020 |
Why?
|
Massachusetts | 2 | 2011 | 8835 | 0.020 |
Why?
|
Adolescent | 6 | 2014 | 88247 | 0.020 |
Why?
|
Killer Cells, Natural | 2 | 1991 | 2191 | 0.010 |
Why?
|
Organizational Culture | 1 | 2008 | 509 | 0.010 |
Why?
|
Pilot Projects | 2 | 2013 | 8619 | 0.010 |
Why?
|
Flow Cytometry | 2 | 1994 | 5863 | 0.010 |
Why?
|
Patient Preference | 1 | 2012 | 925 | 0.010 |
Why?
|
DNA Repair | 1 | 2013 | 2043 | 0.010 |
Why?
|
Immunization | 1 | 1988 | 1217 | 0.010 |
Why?
|
Central Nervous System Neoplasms | 1 | 2012 | 915 | 0.010 |
Why?
|
Mouth Neoplasms | 1 | 1989 | 596 | 0.010 |
Why?
|
Palliative Care | 1 | 2019 | 3593 | 0.010 |
Why?
|
Methotrexate | 2 | 2003 | 1716 | 0.010 |
Why?
|
Abdominal Pain | 1 | 2010 | 1070 | 0.010 |
Why?
|
Lipopolysaccharides | 1 | 1991 | 2202 | 0.010 |
Why?
|
Diarrhea | 1 | 2010 | 1317 | 0.010 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 2270 | 0.010 |
Why?
|
Lumbar Vertebrae | 2 | 2003 | 1874 | 0.010 |
Why?
|
Residence Characteristics | 1 | 2012 | 2092 | 0.010 |
Why?
|
Caspases | 1 | 2005 | 878 | 0.010 |
Why?
|
Adiponectin | 1 | 2008 | 1107 | 0.010 |
Why?
|
Research Design | 1 | 1998 | 6174 | 0.010 |
Why?
|
Motivation | 1 | 2012 | 2003 | 0.010 |
Why?
|
Glioblastoma | 3 | 1993 | 3481 | 0.010 |
Why?
|
Interleukin-6 | 1 | 2012 | 3205 | 0.010 |
Why?
|
Patient Education as Topic | 1 | 2012 | 2315 | 0.010 |
Why?
|
Syndrome | 1 | 2008 | 3268 | 0.010 |
Why?
|
Immunotherapy | 1 | 1997 | 4642 | 0.010 |
Why?
|
Aspirin | 1 | 2013 | 3127 | 0.010 |
Why?
|
Florida | 1 | 2002 | 429 | 0.010 |
Why?
|
Qualitative Research | 1 | 2012 | 3017 | 0.010 |
Why?
|
Cell Line, Tumor | 2 | 2010 | 16968 | 0.010 |
Why?
|
Osteocalcin | 1 | 2001 | 274 | 0.010 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2012 | 3492 | 0.010 |
Why?
|
Bone Density Conservation Agents | 1 | 2008 | 794 | 0.010 |
Why?
|
Stem Cells | 1 | 2013 | 3514 | 0.010 |
Why?
|
Antigens, Neoplasm | 1 | 1988 | 1985 | 0.010 |
Why?
|
Tumor Microenvironment | 1 | 2013 | 3868 | 0.010 |
Why?
|
Patient Satisfaction | 1 | 2013 | 3451 | 0.010 |
Why?
|
Curriculum | 1 | 2013 | 3739 | 0.010 |
Why?
|
Cryotherapy | 1 | 2001 | 159 | 0.010 |
Why?
|
Transplantation, Homologous | 1 | 1988 | 4802 | 0.010 |
Why?
|
Mice, Inbred BALB C | 1 | 1988 | 6188 | 0.010 |
Why?
|
Gastrointestinal Diseases | 1 | 2008 | 1202 | 0.010 |
Why?
|
Medicaid | 1 | 2012 | 2814 | 0.010 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2008 | 2008 | 0.010 |
Why?
|
False Negative Reactions | 2 | 1990 | 573 | 0.010 |
Why?
|
Back Pain | 1 | 2003 | 545 | 0.010 |
Why?
|
Software | 1 | 2013 | 4432 | 0.010 |
Why?
|
Morbidity | 1 | 2004 | 1750 | 0.010 |
Why?
|
Delayed-Action Preparations | 1 | 2002 | 962 | 0.010 |
Why?
|
Sex Factors | 1 | 2012 | 10549 | 0.010 |
Why?
|
Radiopharmaceuticals | 1 | 2008 | 2650 | 0.010 |
Why?
|
Leg | 1 | 2003 | 1087 | 0.010 |
Why?
|
Gonadal Steroid Hormones | 1 | 2002 | 702 | 0.010 |
Why?
|
Spinal Neoplasms | 1 | 2004 | 703 | 0.010 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2003 | 491 | 0.010 |
Why?
|
Genomics | 1 | 2013 | 5822 | 0.010 |
Why?
|
Bone Resorption | 1 | 2001 | 723 | 0.010 |
Why?
|
False Positive Reactions | 2 | 1990 | 957 | 0.010 |
Why?
|
Heart | 1 | 1991 | 4403 | 0.010 |
Why?
|
B-Lymphocytes | 1 | 1991 | 4745 | 0.010 |
Why?
|
Lipids | 1 | 2008 | 3332 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2006 | 6305 | 0.010 |
Why?
|
Young Adult | 2 | 2014 | 59191 | 0.010 |
Why?
|
C-Reactive Protein | 1 | 2008 | 3820 | 0.010 |
Why?
|
Up-Regulation | 1 | 2005 | 4117 | 0.010 |
Why?
|
Contrast Media | 1 | 2009 | 5305 | 0.010 |
Why?
|
Histiocytoma, Benign Fibrous | 1 | 1996 | 64 | 0.010 |
Why?
|
Hemoglobins | 1 | 2002 | 1524 | 0.010 |
Why?
|
Scrotum | 1 | 1996 | 116 | 0.010 |
Why?
|
Ureteral Obstruction | 1 | 1997 | 293 | 0.010 |
Why?
|
Blotting, Southern | 1 | 1996 | 777 | 0.010 |
Why?
|
Neuroblastoma | 2 | 1993 | 1248 | 0.010 |
Why?
|
Kidney | 1 | 1991 | 7044 | 0.010 |
Why?
|
Pain | 2 | 2003 | 5062 | 0.010 |
Why?
|
Health Services Research | 1 | 2002 | 1808 | 0.010 |
Why?
|
Paraffin Embedding | 1 | 1996 | 302 | 0.010 |
Why?
|
Cell Division | 2 | 1994 | 4457 | 0.010 |
Why?
|
Physical Examination | 1 | 2001 | 1254 | 0.010 |
Why?
|
T-Lymphocytes | 2 | 1990 | 10175 | 0.010 |
Why?
|
Insulin Resistance | 1 | 2008 | 3954 | 0.010 |
Why?
|
Ploidies | 1 | 1994 | 285 | 0.010 |
Why?
|
Life Expectancy | 1 | 2001 | 1242 | 0.010 |
Why?
|
Abdomen | 1 | 2000 | 1128 | 0.010 |
Why?
|
Sclerosis | 1 | 1994 | 210 | 0.010 |
Why?
|
Liposarcoma | 1 | 1996 | 289 | 0.010 |
Why?
|
Safety | 1 | 1997 | 1149 | 0.010 |
Why?
|
Blood Pressure | 1 | 2008 | 8473 | 0.010 |
Why?
|
Pelvic Neoplasms | 1 | 1994 | 247 | 0.010 |
Why?
|
Lung | 1 | 1991 | 9999 | 0.010 |
Why?
|
Leiomyosarcoma | 1 | 1996 | 422 | 0.010 |
Why?
|
Colonic Neoplasms | 2 | 1993 | 2533 | 0.010 |
Why?
|
Signal Transduction | 1 | 2013 | 23415 | 0.010 |
Why?
|
Bone and Bones | 1 | 2001 | 2565 | 0.010 |
Why?
|
Deuterium | 1 | 1990 | 106 | 0.010 |
Why?
|
Pharyngeal Neoplasms | 1 | 1990 | 113 | 0.010 |
Why?
|
Mesothelioma | 1 | 1996 | 807 | 0.010 |
Why?
|
Cell Aggregation | 1 | 1990 | 239 | 0.010 |
Why?
|
Obesity | 1 | 2012 | 12934 | 0.010 |
Why?
|
Mitotic Index | 1 | 1989 | 162 | 0.010 |
Why?
|
Species Specificity | 1 | 1993 | 2410 | 0.010 |
Why?
|
Bromodeoxyuridine | 1 | 1989 | 310 | 0.010 |
Why?
|
Immunophenotyping | 1 | 1994 | 1864 | 0.010 |
Why?
|
Thrombocytopenia | 1 | 1997 | 1182 | 0.000 |
Why?
|
Nitrates | 1 | 1990 | 263 | 0.000 |
Why?
|
Attitude of Health Personnel | 1 | 2002 | 3882 | 0.000 |
Why?
|
Radiation Tolerance | 1 | 1990 | 478 | 0.000 |
Why?
|
Polymerase Chain Reaction | 1 | 1996 | 6074 | 0.000 |
Why?
|
Base Sequence | 1 | 1996 | 12420 | 0.000 |
Why?
|
Child | 1 | 2012 | 80089 | 0.000 |
Why?
|
Molecular Sequence Data | 1 | 1996 | 17630 | 0.000 |
Why?
|
Hemorrhage | 1 | 1995 | 3418 | 0.000 |
Why?
|
Triglycerides | 1 | 1990 | 2459 | 0.000 |
Why?
|
Transcription, Genetic | 1 | 1996 | 7583 | 0.000 |
Why?
|
Cell Cycle | 1 | 1989 | 2929 | 0.000 |
Why?
|
RNA, Messenger | 1 | 1996 | 12759 | 0.000 |
Why?
|
Macrophages | 1 | 1990 | 5758 | 0.000 |
Why?
|
Models, Biological | 1 | 1990 | 9461 | 0.000 |
Why?
|
Cardiovascular Diseases | 1 | 1990 | 15498 | 0.000 |
Why?
|